These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31480389)

  • 1. Highlights in Resistance Mechanism Pathways for Combination Therapy.
    Delou JMA; Souza ASO; Souza LCM; Borges HL
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
    Bagnyukova TV; Serebriiskii IG; Zhou Y; Hopper-Borge EA; Golemis EA; Astsaturov I
    Cancer Biol Ther; 2010 Nov; 10(9):839-53. PubMed ID: 20935499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Combinations, How Far We can Go Through?
    Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
    Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Curcumin the Answer to Future Chemotherapy Cocktail?
    Kong WY; Ngai SC; Goh BH; Lee LH; Htar TT; Chuah LH
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review.
    Memariani Z; Abbas SQ; Ul Hassan SS; Ahmadi A; Chabra A
    Pharmacol Res; 2021 Sep; 171():105264. PubMed ID: 33166734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance to targeted therapies: déjà vu all over again.
    Groenendijk FH; Bernards R
    Mol Oncol; 2014 Sep; 8(6):1067-83. PubMed ID: 24910388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
    Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
    Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the Pathways of Resistance to Targeted Therapies.
    Wood KC
    Cancer Res; 2015 Oct; 75(20):4247-51. PubMed ID: 26392071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
    Hu X; Xuan Y
    Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer drugs: How to select small molecule combinations?
    Nussinov R; Yavuz BR; Jang H
    Trends Pharmacol Sci; 2024 Jun; 45(6):503-519. PubMed ID: 38782689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted agents: the rules of combination.
    Kwak EL; Clark JW; Chabner B
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs in refractory colorectal cancer.
    Nobili S; Galletta A; Brugia M; Tassi R; Petreni P; Landini I; Mini E
    Future Med Chem; 2015 Aug; 7(12):1491-501. PubMed ID: 26293581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance.
    Murray BW; Miller N
    Mol Cancer Ther; 2015 Sep; 14(9):1975-84. PubMed ID: 26264276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
    Knudsen ES; Witkiewicz AK
    Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular-targeted agents combination therapy for cancer: developments and potentials.
    Li F; Zhao C; Wang L
    Int J Cancer; 2014 Mar; 134(6):1257-69. PubMed ID: 23649791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: An emerging targeting candidate.
    Afrashteh Nour M; Hajiasgharzadeh K; Kheradmand F; Asadzadeh Z; Bolandi N; Baradaran B
    Life Sci; 2021 Aug; 278():119557. PubMed ID: 33930371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms for tumour resistance to chemotherapy.
    Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
    Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.